Funding round brings in $18M for inflammatory drug developer

04/8/2013 | MedCityNews.com

Aquinox Pharmaceuticals, which develops small-molecule therapies for inflammatory disorders, raised $18 million in a Series C funding round from investors including Pfizer and Johnson & Johnson's venture units. The firm says midstage trials of AQX-1125, its lead drug candidate, could begin within months in patients with chronic obstructive pulmonary disease and interstitial cystitis.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX